Hemophilia B (Factor IX Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Its treatment includes replacing the defective clotting factor.
The Hemophilia B pipeline market research report provides comprehensive information on the therapeutics under development for Hemophilia B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemophilia Band features dormant and discontinued projects.
Key Targets in the Hemophilia B Pipeline Products Market
The key targets in the Hemophilia B Pipeline products market are Coagulation Factor IX, Coagulation Factor VII, Tissue Factor Pathway Inhibitor, Coagulation Factor X, Antithrombin III, and Vitamin K Dependent Protein C.
Hemophilia B Pipeline Products Market Analysis by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Hemophilia B Pipeline Products Market
The key mechanisms of action in the Hemophilia B pipeline products market are Coagulation Factor IX Activator, Coagulation Factor IX Replacement, Coagulation Factor VII Replacement, Tissue Factor Pathway Inhibitor Inhibitor, Coagulation Factor X Activator, Antithrombin III Inhibitor, and Vitamin K Dependent Protein C Inhibitor.
Hemophilia B Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights, download a free report sample
Key Routes of Administration in the Hemophilia B Pipeline Products Market
The key routes of administration in the Hemophilia B pipeline products market are intravenous, subcutaneous, parenteral, and intravenous bolus.
Hemophilia B Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Hemophilia B Pipeline Products Market
The key molecule types in the Hemophilia B pipeline products market are gene therapy, recombinant protein, gene-modified cell therapy, monoclonal antibody, fusion protein, protein, recombinant enzyme, antibody, and antisense RNAi oligonucleotide.
Hemophilia B Pipeline Products Market Analysis by Molecule Types
For more molecule type insights, download a free report sample
Major Companies in the Hemophilia B Pipeline Products Market
Some of the major companies in the Hemophilia B pipeline products market are OPKO Health Inc, Pfizer Inc, Catalyst Biosciences Inc, Freeline Therapeutics Holdings Plc, LFB SA, Novo Nordisk AS, Sanofi, SK Plasma Co Ltd, AlphaMab Co Ltd, and Amarna Therapeutics BV.
Hemophilia B Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Hemophilia B Pipeline Products Market Report Overview
Key Targets | Coagulation Factor IX, Coagulation Factor VII, Tissue Factor Pathway Inhibitor, Coagulation Factor X, Antithrombin III, and Vitamin K Dependent Protein C |
Key Mechanisms of Action | Coagulation Factor IX Activator, Coagulation Factor IX Replacement, Coagulation Factor VII Replacement, Tissue Factor Pathway Inhibitor Inhibitor, Coagulation Factor X Activator, Antithrombin III Inhibitor, and Vitamin K Dependent Protein C Inhibitor |
Key Routes of Administration | Intravenous, Subcutaneous, Parenteral, and Intravenous Bolus |
Key Molecule Type | Gene Therapy, Recombinant Protein, Gene-Modified Cell Therapy, Monoclonal Antibody, Fusion Protein, Protein, Recombinant Enzyme, Antibody, and Antisense RNAi Oligonucleotide |
Major Companies | OPKO Health Inc, Pfizer Inc, Catalyst Biosciences Inc, Freeline Therapeutics Holdings Plc, LFB SA, Novo Nordisk AS, Sanofi, SK Plasma Co Ltd, AlphaMab Co Ltd, and Amarna Therapeutics B |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Amarna Therapeutics BV
ASC Therapeutics Inc
Belief Biomed Inc
Biocad
Catalyst Biosciences Inc
Centessa Pharmaceuticals Plc
Chameleon Biosciences Inc
Chengdu Rongsheng Pharmaceutical Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
CSL Ltd
Daiichi Sankyo Co Ltd
Expression Therapeutics Inc
Freeline Therapeutics Holdings Plc
GC Pharma
GeneLeap Biotech
GeneVentiv Therapeutics Inc
Intellia Therapeutics Inc
LFB SA
Logicbio Therapeutics Inc
Novo Nordisk AS
OPKO Health Inc
Pfizer Inc
RegenxBio Inc
Sanofi
Sigilon Therapeutics Inc
SK Plasma Co Ltd
Staidson BioPharma Inc
ToolGen Inc
UBI Pharma Inc
UniQure NV
Zhengzhou Gensciences Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Hemophilia B pipeline products market?
The key targets in the Hemophilia B pipeline products market are Coagulation Factor IX, Coagulation Factor VII, Tissue Factor Pathway Inhibitor, Coagulation Factor X, Antithrombin III, and Vitamin K Dependent Protein C.
-
What are the key mechanisms of action in the Hemophilia B pipeline products market?
The key mechanisms of action in the Hemophilia B pipeline products market are Coagulation Factor IX Activator, Coagulation Factor IX Replacement, Coagulation Factor VII Replacement, Tissue Factor Pathway Inhibitor Inhibitor, Coagulation Factor X Activator, Antithrombin III Inhibitor, and Vitamin K Dependent Protein C Inhibitor.
-
What are the key routes of administration in the Hemophilia B pipeline products market?
The key routes of administration in the Hemophilia B pipeline products market are intravenous, subcutaneous, parenteral, and intravenous bolus.
-
What are the key molecule types in the Hemophilia B pipeline products market?
The key molecule types in the Hemophilia B pipeline products market are gene therapy, recombinant protein, gene-modified cell therapy, monoclonal antibody, fusion protein, protein, recombinant enzyme, antibody, and antisense RNAi oligonucleotide.
-
Which are the major companies in the Hemophilia B Pipeline products market?
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.